SEC Form 4 · accession 0001209191-16-130263
Viridian Therapeutics, Inc.\DE · VRDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Samuel D Riccitelli
Officer — President & CEO · Director
Period of report
Jun 28, 2016
Accepted (ET)
Jun 30, 2016 · 4:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590750
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 28, 2016 | M | 124,251 | $0.00 | A | 539,365 | D | |
| Common StockF2 | Jun 28, 2016 | F | 64,835 | $0.46 | D | 474,530 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | $0.00 | Jun 28, 2016 | M | 124,251 | D | — | — | Common Stock | 124,251 | 0 | D |
Explanation of responses
- F1Each restricted stock unit represents the contingent right to receive the economic equivalent of one share of the Issuer's common stock, payable in shares of common stock, cash or some combination of both, as determined by the Issuer. The restricted stock units reported herein converted into common stock on a one-for-one basis.
- F2Shares withheld to satisfy tax withholding obligations.
- F3On June 17, 2014, the reporting person was granted 745,511 restricted stock units. Under the terms of the restricted stock unit agreement, the final 16-2/3% of the award vested on the two-year anniverary of the grant date and settled on June 28, 2016.